Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia
Open-Label Trial to Evaluate the Efficacy and Safety of the Use of Argatroban in Patients With Heparin-Induced Thrombocytopenia
Sponsor: Ministry of Health, Labour and Welfare, Japan
This PHASE3 trial investigates Heparin-Induced Thrombocytopenia and is currently completed. Ministry of Health, Labour and Welfare, Japan leads this study, which shows 8 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Jan 2026 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Jan 2026 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ministry of Health, Labour and Welfare, Japan
- Tanabe Pharma Corporation
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Fuchū, Japan , Hakodate, Japan , Isehara, Japan , Iwakuni, Japan , Kobe, Japan , Kurume, Japan , Kyoto, Japan , Morioka, Japan , Nagoya, Japan , Sapporo, Japan and 4 more locations